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Abstract 
Pediatric glioblastoma (pGBM) is a lethal cancer with no effective therapies. To understand 
mechanisms of tumor evolution in this cancer, we performed whole genome sequencing with 
linked reads on longitudinally resected pGBM samples. Our analyses showed that all diagnostic 
and recurrent samples were collections of genetically diverse subclones. Clonal composition 
rapidly evolved at recurrence, with less than 8% of non-synonymous single nucleotide variants 
being shared in diagnostic-recurrent pairs. In order to track the origins of the mutational events 
we observed in pGBM, we generated whole genome datasets for two patients and their parents. 
These trios showed that genetic variants could be (i) somatic, (ii) inherited from a healthy parent, 
or (iii) arose de novo in the germlines of pGBM patients. Analysis of variant allele frequencies 
supported a model of tumor growth involving slow-cycling cancer stem cells that give rise to 
fast-proliferating progenitor-like cells and to non-dividing cells. Interestingly, radiation and anti-
mitotic chemotherapeutics did not increase overall tumor burden upon recurrence. These findings 
support an important role for slow-cycling stem cell populations in contributing to recurrences, 
since slow-cycling cell populations are expected to be less prone to genotoxic stress induced by 
these treatments and to accumulate few mutations. Our results highlight the need for new 
targeted treatments that account for the complex functional hierarchies and genomic 
heterogeneity of pGBM.   
 
 
Statement of significance 
Our work challenges several assumptions on the genetic organization of pediatric GBM, and 
highlights mutagenic programs that start during early prenatal development. 
 
 
Introduction 
Pediatric glioblastoma (pGBM) is a lethal brain tumor. Unlike adult GBM, no effective 
therapeutic intervention or standard of care currently exists for this cancer. Despite their 
histological similarities, pGBM is clinically, biologically and molecularly distinct from adult 
GBM (1). Unfortunately, the biological principles uncovered by studying the adult disease have 
not translated to the pediatric malignancy (2). A major breakthrough in understanding the 
molecular principles underlying pGBM stemmed from the discovery that a third of patients 
harbor somatic mutations in H3F3A, a gene encoding the histone variant H3.3 (3,4). Mutations in 
this gene cause one of two amino acid substitutions in H3.3: (i) Mutation of lysine 27 to 
methionine (K27M); (ii) mutation of glycine 34 to arginine (G34R) or valine (G34V). Both types 
of mutations interfere with the wildtype function of H3.3 (5–8), but the H3.3K27M variant has 
been studied more extensively because it is more frequent and trimethylation of K27 has an 
established and important role in repressing gene transcription and compacting chromatin. 
Several experimental models have been used to show that H3F3A mutations can induce cellular 
hyperproliferation on their own, but they need to cooperate with other drivers, including TP53 
mutations, to produce overt malignancies (6,9,10). For the majority of pGBM patients who 
harbor no H3.3 mutations, the early genetic events leading to overt malignancy are not fully 
understood. 
 It is currently believed that pGBM, similarly to other pediatric cancers, is characterized 
by relatively bland genomes (11). Furthermore, H3F3A mutations were shown to be clonal in 
pGBM (12), and to result in global loss of trimethylation of lysine 27 of histone 3 (H3K27me3) 
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in virtually all cells in a tumor (6). These findings have contributed to the view that pGBM might 
have a relatively low level of intratumoral complexity at the genomic and functional level. 
However, a recent report identified differences in mutational signatures between matched 
primary and recurrent pGBM samples using exome sequencing (12).  
 Evidence of subclonal architecture in diffuse intrinsic pontine glioma and pGBM was 
recently provided (13). The authors reanalyzed previously published exome datasets for 36 
pGBM samples and identified evidence for the coexistence of subclones in each tumor. To the 
best of our knowledge, no study to date has systematically assessed subclonal composition and 
evolution in matched pGBM primary and recurrent samples from the same patient using whole-
genome information. Such studies are important because they may allow inference of biological 
principles responsible for tumor evolution and recurrence, and they might identify intergenic 
variants with important roles in the etiology of this cancer. Furthermore, treatment regimens for 
pGBM differ between centers and individual oncologists, raising the possibility that different 
therapeutic approaches might skew recurrences toward the acquisition of specific molecular 
features. The relative rarity of pGBM (adjusted incidence rate of 0.15/0.16 in 100,000 
population) (14) and the lack of standardized practices for surgical resection contribute to the 
scarce availability of diagnostic-recurrent sample pairs for study. 
 New whole-genome technologies that allow sensitive measurements of cellular 
heterogeneity in a single tumor, and documentation of tumor evolution over time, have yet to be 
systematically employed for this malignancy. We hypothesized that whole-genome sequencing 
(WGS) of primary and recurrent tumors, coupled with targeted bioinformatic approaches to 
specifically test for subclonal architecture of each tumor, might bring new insight into the 
intratumoral organization of pGBM and its evolution. Understanding the principles exploited by 
the tumor to escape treatment may have important implications for rationally selecting or 
designing personalized treatment options for these rare and aggressive cancers. 
 
 
Materials and Methods 
 
Human samples  
All samples were collected and used for research with appropriate informed consent and with 
approval by the Health Research Ethics Board of Alberta and the Research Ethics Board of the 
Hospital for Sick Children. Fresh tumor tissue and blood samples from each patient were 
collected by the Clark Smith Brain Tumour biobank at the University of Calgary and the 
Hospital for Sick Children and preserved at either -80°C or in vapor phase liquid nitrogen. For 
selected cases, a portion the fresh tumor material was also allocated for patient-derived xenograft 
preparation (see below). Anagraphical information of sample donors are in Table S2 and Table 
S3.  
 
Patient-derived xenografts  
All mice were used with approval from the Animal Care Committee of the University of 
Calgary. Fresh tumor tissue was gently dissociated by trituration, filtered using a 0.7 µm filter, 
washed and resuspended in sterile DPBS (Gibco). Tumor cells were injected into the right 
striatum of the brains of CB17 SCID mice (Charles River Laboratory). Animals were monitored 
for tumor growth and tumors were isolated when signs of morbidity were observed. Initial tumor 
establishment for patient specimens SM4021 (recurrence of patient 3) and SM4058 (third 
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recurrence of patient 5) took 59 and 41 days respectively. Tumors were then maintained by serial 
in vivo passaging in the brain of SCID mice every 1-2 months or cut into 1 mm x 1 mm tissue 
pieces and cryo-stored in 1 mL CryoStor CS10 solution (Stem Cell) for 10 minutes on ice prior 
to being stored at -80ºC. In experiments where cryo-stored tissue was used, tissue was thawed, 
dissociated into a single-cell suspension, filtered using a 0.7 µm filter and implanted into the 
brain of SCID mice. All xenografts were identity matched to the original patient material by 
short tandem repeat analysis using the AmpFLSTR Identifiler Plus kit (Applied Biosystems). 
 
Genomic DNA extraction and library preparation  
High molecular weight genomic DNA (gDNA) was extracted from frozen tumor tissue and 
frozen blood samples with the Qiagen MagAttract

 HMW DNA Kit (catalog # 67563). gDNA 
fragment size and distribution were quantified with the Agilent Technologies 2200 TapeStation 
Genomic DNA Assay. Samples with gDNA fragment size > 50 kb were used for library 
construction. The 10xGenomics Chromium
TM
 Genome Library Kit & Gel Bead Kit v2, 16 
reactions (catalog # PN-120258) was used for library preparation. Size and distribution of all 
sequencing libraries were quantified with the Agilent Technologies 2200 TapeStation D1000 
Assay. 
 
Whole-genome sequencing and linked-read data analysis  
Whole-genome sequencing was performed at The Centre for Applied Genomics at the Hospital 
for Sick Children (Toronto, ON) with a HiSeq X Series (Illumina) instrument. Libraries were 
validated on a Bioanalyzer DNA High Sensitivity chip to check for size and absence of primer 
dimers, and quantified by qPCR using Kapa Library Quantification Illumina/ABI Prism Kit 
protocol (KAPA Biosystems). Validated libraries were paired-end sequenced on an Illumina 
HiSeq X platform following Illumina’s recommended protocol to generate paired-end reads of 
150-bases in length. Each library was loaded on a single lane. All libraries were sequenced at 
30x coverage. Post-sequencing, fastq files were analyzed with the package LongRanger-2.1.6 
(10xGenomics) on servers hosted by the Centre for Health Genomics and Informatics 
(University of Calgary, Calgary, AB). LongRanger performed alignment of reads to the 
reference genome (GRCh38), assembled linked-reads, generated haplotype blocks, and called 
single nucleotide polymorphisms and structural variants. LongRanger output files were 
visualized with Loupe browser 2.1.2 (10xGenomics). SNVs were called using both Mutect2 (15) 
and Strelka2 (https://github.com/Illumina/strelka). Only SNVs called by both methods were 
included for downstream analysis. Annotation of SNVs was performed using ANNOVAR (16). 
 
Copy number assays for the ATRX locus  
Custom TaqMan

 Copy Number Assay Probes (catalog # 4400294) from Applied Biosystems
TM 
by Thermo Fisher Scientific were used to detect changes in copy number at the ATRX locus in all 
patients. Quantification was performed according to manufacturers’ protocols. Briefly, for each 
patient, a control DNA sample, patient germline DNA, primary tumor DNA, and recurrent tumor 
DNA were diluted to 5 ng/L. DNA was quantified in triplicates with the Qubit dsDNA HS 
Assay Kit (catalog # Q32851). The TaqMan

 Genotyping Master Mix and TaqMan

 Copy 
Number Assay was added to each well of a 96-well plate. 20 ng of DNA was added in triplicate 
wells of a 96-well plate for each assay condition. The samples were then run on a Bio-Rad CFX 
Connect
TM 
Real-Time PCR Detection System with the following parameters: hold at 95C for 10 
mins, 40 cycles of 95C for 15 sec and 60C for 60 sec. Fluorescence signal for the ATRX 
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putative deleted region (ATRXdel probe) was first normalized to the fluorescence signal from 
the control diploid region probe. Fluorescence was additionally normalized to the diploid control 
DNA sample. TaqMan

 Probes were labeled with FAM at 5’ end and MGBNFQ at the 3’ end. 
For the probe in the ATRX deleted region; probe sequence: 
CACACCCAAATATTGGTAAAAAT, forward primer: TCCAGGACTTAGCAGGATGTGA, 
reverse primer: ACCCCATCAAGTAGATGGTAAGAAACT. For the probe in the control 
diploid region; probe sequence: ACACGGGTGTTGAAGACGC, forward primer: 
AGGCGCTGTGGAAACAATTATAGTA, reverse primer: TGTCCCCGTCAACGATCAC.  
 
Data and software availability 
The linked-read WGS datasets we generated have been deposited to the European Genome-
Phenome Archive (EGA) with accession number EGAS00001003432. scRNA-seq datasets have 
been deposited to the Gene Expression Omnibus (GEO) under accession number GSE117599. 
Bulk RNA-seq data from the Toronto cohort have been deposited to the EGA with accession 
number EGAS00001003070. 
 
 
Results 
 
pGBM samples and whole-genome sequencing with linked-reads  
We characterized longitudinally collected pGBM samples that include primary tumors and their 
recurrences, in addition to peripheral blood (used as germline control), and were biobanked at 
our institution (Calgary cohort). For 4 out of 5 patients we had at least two longitudinal samples 
and for one patient we had three recurrent samples (Table S1). For the purposes of this 
manuscript, diagnostic samples are referred to as "sample 1" and each consecutive resection from 
the same patient is referred to as "sample n." Treatment history for each patient is known (Table 
S2). We also obtained a set of matched germline and primary pGBM samples biobanked in a 
second institution (Toronto cohort) (Table S3) and used these for validation purposes. We 
extracted high molecular weight DNA (average length distribution > 40 kbp) from each sample 
and generated libraries for WGS with linked-read technology (10xGenomics). With this system, 
short next-generation sequencing reads originating from the same DNA molecule (ie an 
individual chromosome fragment) are tagged with an identical barcode, enabling the assembly of 
Mb-size haplotypes from individual chromosomes (Table S4).  
 
Diagnostic and recurrent pGBM samples share few single nucleotide variants  
We used linked-read WGS data for pGBM samples and matched germlines to call somatic 
variants in diagnostic samples and their recurrences. Focusing specifically on non-synonymous 
single-nucleotide variants (nsSNVs), our data are in agreement with previous reports of low 
mutation burden (3,17,18) in pGBM (range: 26-124 SNVs per tumor; average: 65.6 SNVs per 
tumor in primary samples, 60 SNVs per tumor in the recurrences). Overall, we found that 
recurrent tumors shared few somatic mutations with their matched primary malignancies, with 
only between 1 and 5 nsSNVs shared between longitudinal samples from the same patient. This 
translated to an average of 7.8% nsSNVs that were shared between a primary tumor and its 
recurrence. A similar amount (11.8%) of somatic SNVs and indels were shared between 
diagnostic and recurrent samples in the pediatric brain tumor medulloblastoma (19), in contrast 
with the much higher proportion shared between primary and recurrent adult glioma samples 
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(54%) (20). Surprisingly, we observed that the total number of somatic SNVs tended to be stable 
in recurrences post-treatment (Fig. 1A-1E; Supplemental file 1), whereas mutational load is 
known to increase 5-fold at recurrence in pediatric medulloblastoma (19) as well as in adult 
gliomas (20). Patient 1 was one exception (Fig. 1A), but this individual harbored a germline 
deletion of the last exon of TP53 (Fig. S1A and S1B), which might have contributed to 
accelerated tumor evolution by increasing the number of mutational events. Sample 2 had 126 
somatic nsSNVs, and only lesions in ARMC9 and DSE were shared with the diagnostic sample. 
Interestingly, DSE encodes a dermatan sulfarase epimerase and is expressed in the human brain 
at higher levels before birth than after birth (Fig. S1C and S1D). Patient 2 had a somatic 
mutation in H3F3A that was retained in the second sample (Fig. 1B), together with a mutation in 
MUC22 and two nsSNVs in TP53. This patient was treated with temozolomide and local 
radiation (Table S2), which is the standard of care for adult GBM patients. However, the overall 
number of somatic nsSNVs was lower in the second sample (69 SNVs) than in the diagnostic 
sample (109 SNVs), whereas this treatment is known to increase mutational burden in adults. 
This difference in response to chemotherapy and radiation between pGBM and adult GBM was 
also noted in an independent cohort of patients in a recent publication (12). Samples 1 and 2 
from patient 3 only shared a mutation in PCNX (Fig. 1C). Patient 5 had 26 nsSNVs in the 
diagnostic sample and in sample 2, 38 in sample 3, and 39 in sample 4 (Fig. 1D). SNVs in 5 
genes were shared between sample 1, sample 2 and sample 3 (ELAVL2, VWF, KCNJ12, HEXIM2 
and ZNF816). Only SNVs in VWF (encoding the von Willebrand factor) and KCNJ12 (encoding 
an ion channel) were conserved between all samples for this patient.  
No SNV was shared among all samples. Only 4 genes were mutated in at least two primary 
tumors (Table S5), including VWF. Six genes were mutated in at least two recurrences from 
different patients (Table S6). Our data therefore show that pGBM is characterized by large 
intertumoral genetic heterogeneity and by large evolutionary changes following surgical 
resection and treatment.  
No obvious pattern of gene mutations was observed in our dataset. Gene ontology analysis did 
not identify any significantly enriched class of mutated genes. However, we found that nsSNVs 
in diagnostic samples were significantly enriched for genes with an OMIM entry and linked to 
hereditary syndromes (19.6% of the 321 mutated genes, permutation test p = 0.00082; Fig. 1E, 
Fig. S1E,F). 41.3% of these genes are associated with syndromes of the central nervous system 
(CNS). Similarly, nsSNVs in subsequent resections had a significant enrichment for genes with 
OMIM entries (20.2% of the 420 mutated genes, permutation test p < 10
-5
; Fig. S1E,F), and 
35.2% of these genes were associated with hereditary CNS syndromes (Fig. 1F). These 
observations suggest that disruption of multiple unrelated networks of genes may be sufficient 
for pGBM initiation and progression. The identification of nsSNVs in genes linked to hereditary 
syndromes is intriguing, given the early-life onset of this malignancy.  
 
Germline sequencing of mother-father-patient trios  
Intrigued by the identification of somatic nsSNVs in genes associated with hereditary disorders, 
we asked whether pGBM behaves as a developmental syndrome. We reasoned that if we 
assumed cancer was a developmental disorder of progressive mutagenesis, individual patients 
might undergo systemic accumulation of mutations over time. We decided to investigate this 
possibility by assembling trios composed of mother, father and patient, implementing an 
approach similar to what is done with genetic disorders. We were able to obtain the germlines 
(peripheral blood) of the parents of patient 1 and patient 3, and used them for WGS with linked 
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reads. Analysis of these trios enabled us to categorize nsSNVs as either unique to the pGBM 
patient germline (ie not found in either parent’s germline), or inherited from one of the parental 
genomes. Our data show that a TP53 germline variant identified in patient 1 (Fig. S1A and S1B) 
was inherited from one of the parents. In addition, nsSNVs in 9 genes were identified uniquely in 
the germline of this patient (Fig. 1G). Among these genes, RASAL2 encodes a RasGAP and is a 
tumor suppressor (21); PARP4 encodes a member of the poly(ADP)-ribose family, and was 
recently shown to be mutated in the germlines of patients with thyroid and breast cancer (22); 
HUWE1 encodes an E3 ubiquitin ligase that was shown to be a tumor suppressor in mouse 
models of skin cancer (23) and colorectal cancer (24). Similarly, we called 4 de novo nsSNVs in 
the germline of patient 3 (Fig. 1H). Among these genes, KIAA1551 was recently identified as a 
candidate tumor suppressor and is frequently deleted in different cancer types (25). Overall, we 
noticed a significant increase in the number of short (30-50,000 bp) deletions in the germlines of 
pGBM patients (n = 8) compared to the control (parental) germlines (n = 4) we sequenced (Mann 
Whitney test p = 0.0040; Fig. S1G). This collection of sequenced trios is a unique dataset in the 
context of pGBM and offers a new perspective on the emergence of germline variants in 
pediatric patients with sporadic cancer. 
 
Subclonal architecture of pGBM at diagnosis and recurrence  
We next asked whether the small proportion of SNVs shared between each diagnostic sample 
and its recurrence corresponded to an unexpected intratumoral genomic complexity and 
consequent clonal selection. We assessed the presence of genetically distinct subclonal cell 
lineages in each tumor before and after treatment by using somatic mutations and copy number 
alterations to build a genetic phylogeny for each patient using the EXPANDS algorithm (26). 
These phylogenies show that each pGBM and its recurrence(s) are characterized by extensive 
intratumoral genomic heterogeneity and complex subclonal architecture (Fig. 2A-E). These 
results support the presence of multiple genetically distinct subclones that change significantly in 
frequency throughout the evolution of a tumor. Importantly, each recurrent tumor also had a few 
subclones clustering close to the germline, likely indicating the stable presence of early 
(ancestral) clones which are not actively accumulating somatic alterations. This observation is 
best illustrated in patient 5 where three recurrences were available (Fig. 2E). Throughout this 
patient’s tumor progressive divergence from the germline occurs at each successive recurrence in 
a number of genetic lineages, yet a number of ancestral subclones remain detectable at all 
timepoints (e.g. 2agh at the first recurrence; 3f at the second recurrence; 4ef at the third 
recurrence). While these subclones likely had ancestral roles in the early part of the evolutionary 
path of this patient’s tumor, each subsequent recurrence is marked by distinct lineages that have 
diverged significantly from this baseline. 
Having already inferred the phylogenetic lineages present in each sample let us select 
SNVs corresponding to distinct clusters of subclones, such that we could then compare the range 
of mutation signatures from subclones within each sample. In each patient we see evidence for 
multiple mutation signatures, indicating the influence of more than one mutagenic process.  For 
instance, in the diagnostic sample of patient 2, the subclones clustering near the germline 
(1bcfhij) were characterized by mutational signatures 3, 4, 6, and 24, while the more 
evolutionarily divergent subclones accumulated mutations dominated by signatures 4, 6 and 1 
(Fig. 2C). Similar patterns of divergence between mutational signatures specific to clusters of 
subclones were observed for all other patients (Fig. 2B-E and Fig. S2). All together, these data 
indicate that different mutational processes may operate at different times during the evolution of 
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individual tumors. Alternatively, different mutational processes are acting concurrently at the 
onset, and the changing selective pressure present at each treatment stage enables different 
genetic lineages to become dominant within the tumor. 
 
Identification of structural variants in pGBM  
pGBM is known to harbor somatic structural variants (SVs), some of which recur at low 
frequency in the patient population (27,28). Because WGS with linked reads data are optimal for 
identification and visualization of structural variants and subclonal events, we explored the 
behavior of SVs during tumor evolution. SVs were called with the LongRanger package. We 
defined large SVs as variants affecting > 30 kbp of the genome. We processed our linked-read 
WGS data for germlines and tumors independently of each other. This approach allowed us to 
retain SVs that might be important for tumor etiology, but that would otherwise have been 
filtered out because they are also present in the germlines. With this approach, we identified 20 
to 30 SVs in the germlines of each pGBM patient compared to the reference genome (Fig. 3A-E; 
Supplemental file 2). The overall number of large SVs did not change dramatically between the 
primary and recurrent tumors. Patient 1 was the only one displaying a large increase in the 
number of SVs in the primary tumor compared to the germline (Fig. 3A). This was probably 
because of chromosome 6 chromothripsis events, which represented 62% of total SVs for this 
patient. No trace of chromosome 6 chromothripsis was observed in the second resection and the 
total number of SVs was similar to the germline. This was unexpected because most patients 
were treated with radiation, which is known to induce SVs. However, this absence is in accord 
with the observed divergent clonal structure of pGBM (Fig. 2), and suggests that the 
chromothriptic event may have been present in a subclone. Adult gliomas experience a large 
number of mutational events (SVs and SNVs) during standard of care treatment (radiation plus 
temozolomide) (20). Patient 2 underwent radiation and temozolomide treatment, yet the overall 
mutational burden did not drastically increase (Fig. 3B). We detected SVs affecting previously 
known cancer genes as well. Sequencing data provide evidence of a duplication of NTRK2, the 
overexpression of which was previously shown to contribute to tumor metastasis (29). Gene 
fusions involving NTRK2 have been previously reported in pGBM (28). Patient 3 had a somatic 
ETV6-NTRK3 gene fusion in both primary and recurrent tumors. This gene fusion has been 
reported in pGBM before (28), and it was also shown to have oncogenic function in other 
malignancies, including leukemia (30) and breast cancer (31). We also identified a translocation 
predicted to truncate the proto-oncogene MET in patient 4. MET amplifications are relatively 
common in adult GBM (32), and lesions in this gene are known to occur in pGBM (18,28).  
We have identified several SVs that recurred in more than one patient in our cohorts. Among 
these, we found germline deletions affecting the coding sequences of BTNL3, BTNL8, 
APOBEC3A and APOBEC3B (Fig. S3). Interestingly, BTNL8 encodes a cell surface protein 
involved in T cell activation (33), whereas the APOBEC3 genes encode cytidine deaminases with 
roles in antiviral immunity (34). These deletions abrogated gene expression (Fig. S3).  
 
Germline and somatic structural variants during tumor evolution  
In some instances, tumors had lower numbers of SVs than their matched germlines (see 
diagnostic sample in Fig. 3C and samples 2-4 in Fig. 3E). We found that every patient carried 
some germline SVs that were not detected in their diagnostic samples and their recurrences. 
There were 8 such germline-specific SVs for patient 1 (Fig. 3A), 1 for patient 2 (Fig. 3B), 7 for 
patient 3 (Fig. 3C), 9 for patient 4 (Fig. 3D) and 3 for patient 5 (Fig. 3E). Each SV call was 
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made with LongRanger and was manually reviewed, checked for coverage in the region of the 
call and confirmed. Some SVs with allelic frequencies between 0.4 and 0.7 in the germline also 
underwent fluctuations in the tumors, while others were stable (Fig. S4A-D). SVs with allelic 
frequencies > 0.7 in the germline, which we considered clonal, tended to be detected at stable 
levels in primary and recurrent tumors (Fig. S4E-H). The subclonal nature of some SVs in the 
germline, and their fluctuations in primary and recurrent tumors, were unexpected findings and 
we set out to further substantiate these observations. 
 In order to explore the observed SVs with an independent computational method, we re-
called SVs with the GROC-SVs package (35). We subset SV predictions to those for which we 
had sufficient physical coverage in all samples (see Supplemental Methods), thus retaining SVs 
supported by at least 200 barcodes (i.e. DNA molecules) spanning each breakpoint 
(Supplemental file 3). We stratified SVs in each patient based on their pattern of presence or 
absence across samples. For instance, somatic SVs were absent from the germline and appeared 
in one or more tumor samples (Fig. 4). Germline events were detected in all samples, and in 
patients 1 and 3 could be further stratified into those inherited from a parent or occurring de 
novo. In all pGBM patients, we identified changes in SV allelic frequencies between tumor 
resections. Allelic frequency changes could represent loss or acquisition of somatic SVs in the 
tumors (Fig. 4H), and are often observed in our cohort to occur in genes with previous evidence 
for structural variation in pediatric cancers (Fig. 4B,C,G,I) (36). For patient 1, we identified 
several de novo germline SVs (which were not detected in the parents) with allelic frequencies in 
the tumor samples (Fig. 4C). These data point to complex patterns of propagation of SVs from 
the germline to tumor samples, and highlight for the first time the presence of putative de novo 
germline SVs in pGBM patients. 
 
Subclonal deletions at the ATRX locus in germlines and pGBM samples  
The data organization principles underlying linked-read WGS data facilitated identification and 
visualization of subclonal SVs. Among these SVs, we identified large deletions in ATRX that 
removed almost the entire coding region of the gene (Fig. 5A). Somatic SNVs in ATRX are 
known to occur in pGBM (3,37), and loss of ATRX protein is routinely tested in GBM 
specimens in the clinic with immunostaining techniques. Our data indicate that ATRX harbors 
both SNVs and SVs in pGBM. Of note, we detected putative subclonal ATRX deletions in the 
germline of pGBM patients. In order to validate the presence of putative ATRX deletions with an 
independent approach, we designed a TaqMan probe for copy number assays that targets the 
putatively deleted region ("ATRXdel" probe; Fig. 5B; see Materials and Methods). We then 
performed copy number TaqMan assays using genomes from both the germline and the tumors 
of our pGBM patients. This TaqMan assay confirmed the ATRX deletion in both germlines and 
tumors of all pGBM patients with the exception of patient 5, where the deletion was only 
detected in sample 2 (Fig. 5C and Fig. S5). In order to validate these findings in an independent 
cohort, we performed WGS with linked reads on three more pGBM samples and their matched 
germlines collected in Toronto (Table S3). Our data show evidence of subclonal deletions at the 
ATRX locus in all samples (Fig. S6A). These findings confirm our WGS and copy number data 
and show that subclonal deletions in ATRX exist in both the germline and tumors of most pGBM 
patients. 
 We expected that subclonal ATRX deletions may result in heterogeneous expression of 
the gene in populations of tumor cells. Since our longitudinal collection was assembled over a 
long period of time, storage of pGBM samples was not compatible with single-cell RNA-seq 
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(scRNA-seq) methods. We therefore decided to assess transcriptional heterogeneity using 
patient-derived xenografts (PDXs), which were available for sample 2 of patient 3 and for 
sample 4 of patient 5. We successfully generated scRNA-seq data for 1,327 cells from patient 3's 
sample 2, and for 2,204 cells patient 5's sample 4. As predicted from the WGS data and TaqMan 
assays, scRNA-seq data showed heterogeneous expression of ATRX in both PDXs (Fig. 5D,E). 
In contrast, other genes, for instance H3F3A and H3F3B (both of which encode the histone 
variant H3.3), were more homogeneously expressed (Fig. S6B,C). Widespread decreased ATRX 
expression in pGBM compared to non-neoplastic brain tissue (n = 4) was confirmed by RNA-seq 
of bulk pGBM tissue (n = 3) and their matched primary cultures from an independent cohort 
collected in Toronto (Fig. 6F). Furthermore, analysis of an independent genomic dataset 
confirmed that subclonal ATRX mutations are detected in the tumors of pGBM patients (Fig. 
S6D). Our data therefore show that in addition to somatic SNVs in ATRX, pGBM patients may 
also carry subclonal ATRX deletions in both their germlines and tumors. 
 
Evidence for the existence of slow-cycling cancer stem cells in pGBM  
We questioned whether the observed variability of the mutational profile might correlate with 
proliferative heterogeneity in the respective contributions made by subclones to tumor growth 
and recurrence. Recently, cell tracing studies based on the genetic barcoding of freshly-isolated 
adult GBM cells transplanted into PDX mouse models have suggested that tumor cells may 
adhere to a common fate behavior, reminiscent of a normal neurogenic program (38). 
Specifically, a signature negative binomial dependence of the distribution of variant allele 
frequencies (VAFs) provides evidence of a conserved proliferative hierarchy in which slow-
cycling tumor stem-like cells give rise to a rapidly cycling, self-renewing, progenitor-like 
population (Fig. 6A) (Extended Data Figure 4 of (38)). Applied to the patient samples in the 
current study, we find that the VAF distribution obtained from tumor samples is also largely 
consistent with a negative binomial dependence (Fig. 6B-E, Fig. S7A-I, Table S7), suggesting 
pGBM tumor cells may be defined by a similar proliferative hierarchy (see Supplemental 
Methods). This conclusion is reinforced by focusing on the ensemble of de novo point mutations 
that are acquired, or only rise above the detection threshold, during recurrence (Fig. S7J-N and 
Supplemental Methods). By contrast, mutations that are shared between the primary and 
recurrent tumor samples show VAFs that are peaked at larger values, consistent with the 
predominance or fixation of subclones within the tumor population (Fig. S7O-R). Our data from 
our pGBM patient cohort are therefore consistent with a hierarchical model for pGBM, 
characterized by slow-cycling cancer stem cells that give rise to fast-proliferating progenitor-like 
cells, which eventually produce non-dividing "differentiated" cells.  
 
 
Discussion 
Cancer is often compared to a caricature of developmental processes. Molecular profiling of 
pGBM suggests that this cancer has features that make it appear like a caricature of hereditary 
disorders. Notwithstanding large differences in terms of mutated genes among tumors, in every 
patient we identified somatic SNVs in several genes linked to hereditary conditions, including 
MeCP2, which is linked to Rett syndrome (39), and autosomal dominant genes linked to severe 
intellectual (ZMYND11, OMIM number 608668)  and developmental syndromes (DSE, linked to 
Ehlers-Danlos syndrome; REEP1, OMIM number 609139). Interestingly, the pediatric brain 
tumor diffuse intrinsic pontine glioma has recurrent somatic mutations in ACVR1 (28,40–42), 
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and germline mutations in this gene lead to the hereditary syndrome fibrodysplasia ossificans 
progressiva (43). The detection of germline variants in pGBM patients, and the identification of 
somatic SNVs in genes associated with hereditary syndromes, give pGBM a characteristically 
different molecular flavor from adult GBM. Because of the early onset of pGBM, studies of 
larger cohorts will be required to determine if germline and somatic events occurring during 
embryonic and/or fetal development cooperatively contribute to pGBM initiation and 
progression. These studies will be particularly important given that currently no genetic or 
environmental factor has been associated with sporadic pGBM. It would be important to 
determine whether the de novo germline variants identified in this study arise in the germ cells of 
the parents during the normal mutagenic processes of genome replication (44), or if they arise 
during early embryonal or fetal development. Our data showing that some variants have low (< 
0.2) allelic frequency in the germline of pGBM patients suggest that these individuals might 
display somatic mosaicism resulting from mutational processes during postzygotic stages of 
development. Interestingly, clonal hematopoiesis has recently been shown to be associated with a 
10-fold increase in risk of developing hematologic cancer (45,46), and was observed in both 
adult and pediatric patients with non-hematologic cancers (47). In pediatric cancer patients, 
clonal hematopoiesis was identified in 5-10% of individuals, with highest frequency in children 
aged 0-9 years. There is therefore a possibility that some subclonal SVs with < 0.2 allelic 
frequencies in the germline that became barely detectable or undetectable in tumors might reflect 
clonal hematopoiesis. In this scenario, the frequency of germline SVs in the tumor may depend 
on the extent of tumor infiltration of hematopoietic cells carrying that specific SV. However, we 
identified this phenomenon in all pGBM samples, which is more than expected based on 
available published data (47). The low allelic frequency of some germline SVs is therefore more 
likely the result of developmental processes that selected them over time. 
By sequencing the germlines of trios, our data provide an important perspective on the 
developmental origins of pGBM. Our data show that some potentially deleterious germline 
variants (like a TP53 exonic deletion in patient 1) can be inherited from a healthy parent. At the 
same time, we observed de novo nsSNVs in the germlines of both patient 1 and patient 3, as well 
as de novo germline SVs in patient 1. The expected rates of emergence of de novo nsSNVs is 
very low, based on recent literature evidence on trios that included probands affected by 
disorders with high heritability (48,49). While acknowledging that our sample set is small and 
that there may be differences in numbers of SNVs detected and called based on sequencing 
platform and computational pipelines used in these studies, our data offer proof-of-principle that 
mutational processes are at play in the parents' germ cells or in the early developing zygote 
leading to de novo germline variants in at least some pGBM patients. Because of the rare nature 
of pGBM, and difficulties in re-contacting families of pGBM patients, the trios we generated 
represent extremely valuable resources. In the future, it will be important to assemble germline 
WGS data on trios of pGBM probands in a systematic fashion, in order to assess and investigate 
genomic predisposing events. 
Using WGS data with linked reads, we have identified a set of germline SVs that tend to occur at 
high frequency in our cohort. One of these examples is subclonal deletions at the ATRX locus in 
both germlines of four out of five patients and tumor tissues of all patients. Recent work showed 
that deletion of Atrx in mouse neural progenitor cells or ATRX in adult glioma stem cells alters 
patterns of chromatin openness genome-wide and leads to enhanced cell migration (50). Because 
of the established involvement of ATRX in gliomagenesis, we speculate that ATRX deletions 
might be a predisposing genetic lesion for pGBM.  
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Importantly, our analyses show that pGBM is characterized by intratumoral genetic 
heterogeneity and subclonal architecture, which rapidly evolves at recurrence. Our work, 
together with previous reports on pediatric medulloblastoma (19) and diffuse intrinsic pontine 
glioma (13), indicates that pediatric brain cancers have more complex genetic architectures than 
previously thought. The genetic divergence between diagnostic and recurrent samples should be 
kept into consideration when designing personalized treatment approaches. In addition to genetic 
heterogeneity, our data provide evidence for the existence of a functional hierarchy in pGBM. 
VAF distributions in pGBM samples are consistent with a hierarchy comprising slow-cycling 
cancer stem cells, fast-proliferating progenitor cells and non-self-renewing and non-dividing 
cells destined to undergo cell death. Single-cell barcoding experiments with xenografts derived 
from adult GBM patients supported a similar hierarchy (38). Although adult GBM and pGBM 
are molecularly different, hierarchical organization may be a common feature of both. If slow-
cycling, self-renewing cancer stem cells reside at the apex of a pGBM hierarchy, these cells 
might be less sensitive to radiation and antimitotics used to treat this cancer, explaining why 
recurrences did not have a significantly higher mutational burden than the diagnostic samples. 
Whereas temozolomide and radiation treatment significantly increased the mutational burden in 
recurrences in adult GBM, it did not have this effect in pGBM. We propose that this might be 
because the cancer stem cell population might be more quiescent in pGBM than in adult GBM. 
Alternatively, it is possible that other biological differences between pGBM and adult GBM play 
a role.  
Overall, our data provide strong evidence for the existence of subclonal architecture in pGBM 
and relatively rapid evolution at recurrence, irrespective of treatment. Reconstruction of mother-
father-patient trios revealed the potential for inherited and de novo germline variants and somatic 
mutations to contribute to the etiology of this pediatric cancer. 
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FIGURE LEGENDS 
 
Fig. 1. Single nucleotide variants in pediatric GBM samples.  
(A-D) Sankey plots for patients 1 (A), 2 (B), 3 (C), and 5 (D). Each plot illustrates changes in the 
mutational landscapes between primary tumors and recurrences. Bold numbers represent total 
number of mutations in each profiled tumor. Gene lists represent the mutated genes that are 
shared between consecutive tumors.  
(E) Analysis of all exonic, non-synonymous single nucleotide variants (nsSNVs) in all primary 
tumors reveals a fraction of genes are associated with hereditary syndromes, according to the 
OMIM database. Out of the 63 genes with links to hereditary disease, 26 were specifically linked 
to central nervous system (CNS) syndromes.  
(F) Analysis of all exonic, nsSNVs in all recurrent tumors. Out of 85 genes with links to 
hereditary disease, 30 were specifically linked to CNS syndromes. 
(G) Germlines were sequenced for patient 1, and the patient's mother and father. A deletion of 
the last exon of TP53 was detected in the father, and it was inherited by patient 1. Non-
synonymous SNVs in 9 other genes were identified in patient's 1 germline, but not in the parents. 
(H) De novo non-synonymous SNVs in four genes were identified in patient's 3 germline.  
 
Fig 2. Subclonal architecture and evolution in pGBM. 
Phylogenetic trees reflect intermixing of genetic lineages in each sample from patients 1 (A), 2 
(B), 3 (C), 4 (D), and 5 (E).  The subclonal structure of each tumor sample was inferred using 
somatic mutations and copy number alterations. Distance between nodes is proportional to the 
number of genetic differences between subclones. Branch tips are color-coded according to 
sample number, and labeled according to sample number (1, 2, 3) and clonal lineage (a, b, c). For 
selected clusters of genetic subclones, pie charts display the contribution of mutational signatures 
detectable using the somatic mutations specific to those phylogenetic branches.  
 
Fig. 3. Number of large structural variants (SVs) in the germlines and pGBM tumor tissue.  
Total number of large SVs in the germline, primary and recurrent tumors for patients 1 (A), 2 
(B), 3 (C), 4 (D), and 5 (E). SV calls were performed with the LongRanger pipeline. 
 
Fig. 4. Dynamic contributions of structural variants to tumor genomes.  
Allelic frequencies for structural variants called by GROC-SVs are plotted across samples for all 
patients (patient 1 (A), patient 2 (D), patient 3 (E), patient 4 (F), and patient 5 (H)).  Red lines 
connect dots that represent the allelic frequency of 10x barcodes supporting a particular SV, such 
that higher values represent a higher level of support for the SV. Only SVs with a minimum of 
200 barcodes in each patient sample are shown.  Red vertical lines highlight samples for which 
an SV was confidently called in the corresponding sample. Inset gene names represent genes 
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shown in panels B, C, G, and I.  Samples include the germline for primary tumors and their 
recurrences, and germlines of the parents of patient 1 and patient 3. In these patients, germline 
events are stratified into inherited vs de novo events, and those observed in both parental 
germlines were excluded unless they were absent in another sample. Panels (B), (C), (G), and (I) 
contain gene level diagrams of select SVs that occur in genes previously associated with 
pediatric cancers. Gene diagrams include exon boundaries (dashed horizontal lines), protein 
domains (colored boxes, only including domains overlapping the SV breakpoint), previously 
annotated somatic alterations in pediatric cancers (lollipops above the gene diagram), and the 
breakpoint observed in a particular patient (larger lollipop below the gene diagram).  For SV 
events spanning genes ADGRB1-BAHCC1, GRM4-SYT2, and GPA33-SEPT9, the predicted 
effect of the structural variant on the structure of the genes is shown below the main gene model. 
 
Fig. 5. Subclonal ATRX deletions in the germline and tumors of pGBM patients.  
(A) Putative subclonal deletions at the ATRX locus in a tumor from a pGBM patient.  
(B) Diagram describing the binding locations of a TaqMan probe (ATRXdel) designed to detect 
copy number variations at the ATRX locus.  
(C) TaqMan assays to detect copy number variation at the ATRX locus on samples for patient 4. 
T-test statistics was used to obtain p-values. 
(D) Single-cell RNA-seq in a xenograft derived from patient's 3 recurrence. ATRX expression 
levels are represented in this tSNE plot.  
(E) Single-cell RNA-seq data for recurrence 3 of patient 5. This tSNE plot displays expression 
levels for ATRX.   
(F) RNA-seq data for ATRX expression in non-neoplastic brain tissues (n = 4), bulk pGBM 
samples (n = 3) and their matched primary cultures (n = 3). ATRX expression was normalized to 
the average for non-neoplastic brain tissues. P-values were derived from t-test statistics. 
 
Fig. 6. Evidence for a hierarchical organization of pGBM. 
(A) Diagram illustrating a testable model for pGBM organization and growth. Under a 
hierarchical model that includes slow-cycling cancer stem cells giving rise to proliferating 
progenitor cells and non-proliferating cells, the incomplete moment of variant allele fractions 
(VAFs) would follow a negative binomial distribution. 
(B-E) Fit of the first incomplete moment of the VAF distribution based on a neutral hierarchical 
model of tumor cell dynamics (red line) to data obtained from patient 5 (black points). The grey 
lines indicate allele frequency cut-offs due to sequencing resolution (lower) and ploidy (upper).  






